Clinical trial readout dates for Supernus Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
| Phase 1/2 BIS-001ER Focal Impaired Awareness Seizures · NCT03474770 | December 2026 Ongoing |
| Phase 2 SPN-821 2400 mg Major Depressive Disorder (MDD) · NCT07226661 | December 2026 Recruiting |
| Phase 2 SPN-817 Focal Onset Seizures · NCT06798896 | August 2027 Recruiting |
| Phase 2 SPN-817 Epilepsy; Seizures, Epileptic · NCT05518578 | December 2027 Recruiting |
| Phase 2 SPN-817 Focal Onset Seizures · NCT07141329 | December 2027 Enrolling |
Supernus Pharmaceuticals Inc. reported $305M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). It reported net income of $137M for that quarter.
| 8-K Reg FD Disclosure — often a data announcement | 2026-11-02 |
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-10-29 |
| 8-K Other Events — often topline trial data | 2026-10-22 |